Blockbuster Hopes Grow for Ablynx Arthritis Drug Backed by AbbvieBlockbuster Hopes Grow for Ablynx Arthritis Drug Backed by Abbvie

Ablynx's hopes for a potential multibillion-dollar drug were boosted on Thursday by strong clinical trial results in rheumatoid arthritis, vindicating a $175 million bet placed on the product by U.S. pharma group AbbVie in 2013. Reuters Health Information
Source: Medscape Orthopaedics Headlines - Category: Orthopaedics Tags: Rheumatology News Source Type: news